Last reviewed · How we verify
Clinical Study of BRL-101 in Severe SCD
This is a single center, non-randomized, open label, single-dose study in subjects with Sickle Cell Disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (BRL-101).
Details
| Lead sponsor | Bioray Laboratories |
|---|---|
| Phase | NA |
| Status | ENROLLING_BY_INVITATION |
| Enrolment | 3 |
| Start date | Mon Jul 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Jun 15 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Sickle Cell Disease
Interventions
- BRL-101
Countries
China